Pramodini Medicare Ltd.
SMEBSE₹110–118
₹ 53 Cr
2400 Shares
₹ 2,64,000
₹10
Financial Summary
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| 6,228.75 | 3,823.77 | |
| 109.09 | 30.86 | |
| 6,337.84 | 3,854.63 | |
| 3,138.39 | 1,727.16 | |
| 2,330.12 | 1,575.11 | |
| 1,737.73 | 1,113.99 |
Subscription Details
IPO Timeline
IPO Offer Start
12 Aug 2026
IPO Offer Ends
14 Aug 2026
19 Aug 2026
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | Funding of capital expenditure for purchase of Medical Equipments | 451.485 |
| 2 | General corporate purposes and unidentified inorganic acquisition | 107.575 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
85.71%
Promoter stake
Post-IPO
62.64%
Promoter stake
Offered to Public
44,90,400
shares
Post Share Capital
1,38,09,077
shares
About the Company
We are a diagnostic service provider in India. We provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. Our diagnostic services include a comprehensive range of offerings: (i) “Radiology” which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, Dexa Scan and Intervention Radiology, (ii) “Clinical Laboratory” which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) “Nuclear Medicine” which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy. We also provide teleradiology services through our registered office situated at Vijayawada which functions on a 24×7 basis throughout the year. We provide healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions. Our services includes both routine and specialized tests, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of diseases.
Use of Proceeds
1. Funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres; and 2. General corporate purposes and unidentified inorganic acquisition.